ANTI-MÜLLERIAN HORMONE (AMH) AND EMBRYO EUPLOIDY IN SUBPOPULATIONS OF WOMEN PURSUING IN VITRO FERTILIZATION (IVF) WITH PREIMPLANTATION GENETIC TESTING

Abstract

While the negative effect of aging on the quantity and quality of oocytes is well established, it is currently unknown whether these processes occur independently. To date, studies which investigated the quantity-quality relationship using embryo aneuploidy as a qualitative marker have primarily focused on the infertile population and produced inconclusive findings (1-2). This study seeks to determine whether AMH, a quantitative biomarker for ovarian reserve, is associated with euploidy rates in two patient populations: the general population of women pursuing IVF with preimplantation genetic testing for aneuploidy (PGT-A) (“infertile” group) and women pursuing IVF with preimplantation genetic testing for monogenic disorders (PGT-M) due to risk for hereditary monogenic diseases (“non-infertile” group).